Inspire Medical Systems, Inc. INSP

What this company does

Inspire Medical Systems has developed a closed-loop system that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. It sells its Inspire system to hospitals and ambulatory surgery centers in the U.S. and in select countries in Europe through a direct sales organization, and sells the system in Japan and Singapore through distributors. As of December 31, 2025, it had 295 sales territories in the U.S. and 21 outside of the U.S. Physicians have treated more than 125,000 patients with Inspire therapy across the United States, Europe, and Asia. As of December 31, 2025, it had 1,333 employees, of which 1,243 are in the U.S., 83 are in Europe, and 7 are in Japan. Inspire therapy received premarket approval from the FDA in 2014 and has been commercially available in certain European markets since 2011.

Written from the business description in Inspire Medical Systems, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 13 February 2026. Every sentence was checked against that document before publication.